Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.

This study reported that weekly intramuscular dexpanthenol may improve quality of life and satisfaction with hair appearance in women with female pattern hair loss, with no side effects observed.

This study found that optimal antioxidant properties of a cream-mask, as indicated by extended Paramecium caudatum motor activity in a toxic environment, were achieved with 10% Sophora japonica tincture and 5% Serenoa repens dry extract.

This review discusses the FDA-approved JAK inhibitor baricitinib as a treatment for alopecia areata, highlighting its dosing regimen, clinical challenges, and the need for additional safety data while exploring the potential of other topical and sublingual JAK inhibitors under investigation.

This study found that most chronic alopecia areata patients treated with azathioprine, methotrexate, or cyclosporine continued treatment for at least 12 months, often requiring concurrent low-dose prednisolone.

This article reviews the use of alitretinoin for corticosteroid-refractory chronic hand eczema and explores its potential therapeutic benefits in other skin conditions, but reports no clinical results.

This study found that using a low-level laser comb led to hair regrowth in a mouse model of alopecia areata, while sham-treated mice showed no hair regrowth.

This study found that combining 7% chamomile extract with 5% minoxidil solution may reduce cutaneous side effects like itching, scaling, and erythema in male patients with androgenic alopecia, potentially improving treatment compliance.

This study developed and validated a simple and cost-effective spectrophotometric method to accurately determine Aminexil in cosmetic formulations containing niacinamide and pyridoxine.

This study found that Ageratum conyzoides extract enhanced hair growth in mice and human follicle cells, showing potential for hormonal modulation, pathway activation, and antioxidant protection; however, further clinical studies are needed to confirm efficacy in humans.

A new microneedle patch effectively and safely treats alopecia areata.

This study found that a novel dietary supplement, AGA-P, when combined with minoxidil and finasteride, significantly improved the clinical efficacy of these drugs for treating mild-to-severe androgenic alopecia compared to drug treatment alone over six months.

This study found that both intralesional steroid injections and Jessener solution were more effective than saline in treating alopecia areata, with no significant difference between the two active treatments.

In this study, aqueous and aqueous-alcoholic extracts of Ajuga reptans showed promising hepatoprotective and wound-healing properties, with significant effects observed in experimental models, suggesting potential for development into official medicinal products pending further research.

In this survey of dermatologists, pimozide was most commonly identified as the preferred first-line antipsychotic for treating delusions of parasitosis, followed by risperidone.

This study reported that long-pulse alexandrite laser treatment achieved an overall hair reduction rate of 80.8% among patients, with minimal cases of hypo- or hyperpigmentation.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

The researchers reported a case of a young girl with alopecia areata who responded well to a combination therapy of 88% phenol and dexamethasone, with no recurrence observed during six months of follow-up.

This study reported that Cosmerna ARI significantly improved androgenetic alopecia in Europeans over a 6-month period compared to a placebo, according to a double-blind, randomized, placebo-controlled clinical trial.

This study found that anti-CD44 treatment inhibited leukocyte migration in alopecia areata and eczema, suggesting targeted therapies could enhance contact sensitizer treatment for alopecia areata.

This study found that a herbal shampoo and solution were more effective than placebo in reducing hair loss and improving hair growth in participants with androgenetic alopecia and telogen effluvium.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This phase 2 trial found that SM04554, a Wnt signaling modulator, was well-tolerated and increased follicle counts in males with androgenetic alopecia, suggesting potential for promoting hair growth.

This report examines efforts to enhance the efficacy of topical steroids for alopecia areata using penetration-enhancing vehicles and exceptionally high concentrations, noting systemic steroids often lead to relapses and toxicity.

In this study, topical azelaic acid cream 20% was observed to show acceptable efficacy for treating localized alopecia areata of the scalp, offering a potential therapeutic alternative to topical clobetasol ointment 0.05%.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

In this case report, azathioprine was linked to anagen effluvium in a 36-year-old woman after two weeks of use; hair regrowth occurred once the drug was stopped and minoxidil treatment was started.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This case report describes the treatment of a 12-year-old female with Alopecia Areata using oral azathioprine.